Authors

• Jin Hyuk Jung
• Tamera J. Corte (ORCID: https://orcid.org/0000-0002-5076-8929)
• Mordechai Reuven Kramer (ORCID: https://orcid.org/0000-0003-2376-2393)
• Jeong H. Yun (ORCID: https://orcid.org/0000-0002-4361-8295)
• Lisa Lancaster (ORCID: https://orcid.org/0000-0001-8465-7357)
• Anand Devaraj
• Peter Myles George (ORCID: https://orcid.org/0000-0003-1316-4891)
• Jin Woo Song (ORCID: https://orcid.org/0000-0001-5121-3522)
• Toby M. Maher (ORCID: https://orcid.org/0000-0001-7192-9149)
• KyungJin Kim
• Lisa Sather
• Sujin Jung
• Jimin Cho

Institutions

• Ulsan College (KR)
• Brigham and Women's Hospital (US)
• Harvard University (US)
• Royal Prince Alfred Hospital (AU)
• Keck Hospital of USC (US)
• Rabin Medical Center (IL)
• Asan Medical Center (KR)
• University of Ulsan (KR)
• Royal Brompton Hospital (GB)
• Samjin Pharm (South Korea) (KR)
• Brainomix (United Kingdom) (GB)
• Integrated BioTherapeutics (United States) (US)
• Atara Biotherapeutics (United States) (US)
• Imperial College London (GB)
• Vanderbilt University Medical Center (US)

Publication Details

Journal

BMJ Open Respiratory Research

Published

2025-05-01

DOI

https://doi.org/10.1136/bmjresp-2024-003038

Citations

5

Primary Topic

Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Type

article

Field-Weighted Citation Impact

7.59

Funders

• Amgen
• Bristol-Myers Squibb
• Pfizer
• AstraZeneca
• Sanofi
• Teva Pharmaceutical Industries
• Celgene
• FibroGen
• United Therapeutics Corporation
• CSL Behring
• Savara Pharmaceuticals
• Galecto
• Veracyte
• National Research Foundation
• National Research Foundation of Korea
• Eisai
• Daewoong Pharmaceutical Company
• Grifols
• Genentech
• National Heart, Lung, and Blood Institute
• Daiichi Sankyo Europe